Monte Rosa Therapeutics, Inc.

Previous wording

Since our inception, we have focused substantially all of our efforts and financial resources on developing our proprietary QuEENTM platform, our proprietary MGD library and our initial pipeline of product candidates. To date, we have financed our operations primarily through the issuance and sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock, registered direct offerings, and through our collaboration with Roche. From our inception through the date hereof, we raised an aggregate of $684.8 million of gross proceeds from such transactions. As of September 30, 2024, our cash, cash equivalents, restricted cash and marketable securities were $247.1 million. We have incurred net losses in each year since our inception, and we had an accumulated deficit of $452.0 million as of September 30, 2024. For the years ended December 31, 2023 and 2022, we reported net losses of $135.4 million and $108.5 million, respectively. For the nine months ended September 30, 2024 and 2023, we reported a net loss of $86.1 million and $102.1 million, respectively. Substantially all of our operating losses have resulted from costs incurred in connection with our research and initial pipeline programs and from general and administrative costs associated with our operations. We expect to continue to incur significant expenses and increasing operating losses over the next several years and for the foreseeable future. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit and working capital. We expect our expenses to significantly increase in connection with our ongoing activities, as we:

Current wording

Since our inception, we have focused substantially all of our efforts and financial resources on developing our proprietary QuEENTM discovery engine, our proprietary MGD library and our initial pipeline of product candidates. To date, we have financed our operations primarily through the issuance and sale of convertible promissory notes, convertible preferred stock, public offerings of our common stock or warrants to purchase common stock, registered direct offerings, and our collaboration agreements with Roche and Novartis. From our inception through the date hereof, we raised an aggregate of $835.8 million of gross proceeds from such transactions. As of March 31, 2025, our cash, cash equivalents, restricted cash and marketable securities were $331.0 million. We have incurred net losses in each year since our inception, and we had an accumulated deficit of $391.7 million as of March 31, 2025. For the years ended December 31, 2024 and 2023, we reported net losses of $72.7 million and $135.4 million, respectively. For the three months ended March 31, 2025 and 2024, we reported a net income of $46.9 million and a net loss of $32.0 million, respectively. Substantially all of our operating losses have resulted from costs incurred in connection with our research and initial pipeline programs and from general and administrative costs associated with our operations. We expect to continue to incur significant expenses and increasing operating losses over the next several years and for the foreseeable future. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ deficit and working capital. We expect our expenses to significantly increase in connection with our ongoing activities, as we:

Previous wording

conduct our clinical trial for MRT-2359, our MGD product candidate targeting GSPT1, and MRT-6160, our MGD product candidate targeting VAV1;

Current wording

conduct our clinical trial for MRT-2359, our MGD product candidate targeting GSPT1;

Previous wording

continue preclinical activities for our VAV1, NEK7, CDK2, CCNE1, and other currently undisclosed programs;

Current wording

continue preclinical activities for our NEK7, CDK2, CCNE1, and other currently undisclosed programs;

Previous wording

prepare and submit IND applications with the FDA for other current and future product candidates, including for MRT-8102, our MGD product candidate targeting NEK7; complete preclinical studies for current or future product candidates;

Current wording

prepare and submit IND applications with the FDA for other current and future product candidates, including for MRT-8102, our MGD product candidate targeting NEK7;

Previous wording

progress MGD molecules from our initial programs through lead optimization to development candidates;

Current wording

progress MGD molecules from our initial programs through lead optimization to development candidates and multiple areas of interest and indication;

Previous wording

expand and improve the capabilities of our QuEENTM platform;

Current wording

expand and improve the capabilities of our QuEENTM discovery engine;

Previous wording

develop and scale up our capabilities to support our ongoing preclinical activities and future clinical trials for our product candidates and commercialization of any of our product candidates for which we may obtain marketing approval; maintain, expand, and protect our intellectual property portfolio;

Current wording

develop and scale up our capabilities to support our ongoing preclinical activities and future clinical trials for our product candidates and commercialization of any of our product candidates for which we may obtain marketing approval;